Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C2YB
|
|||
| Former ID |
DAP000450
|
|||
| Drug Name |
Cefoperazone
|
|||
| Synonyms |
Cefobid; Cefoperazon; Cefoperazono; Cefoperazonum; Cefoperazone sodium salt; Peracef [veterinary]; CP 52640; Cefazone (TN); Cefobid (TN); Cefoperazone (INN); Cefoperazone [INN:BAN]; Cefoperazono [INN-Spanish]; Cefoperazonum [INN-Latin]; Peracef [veterinary] (TN); (6R,7R)-7-((R)-2-(4-Ethyl-2,3-dioxo-1-piperazinylcarboxamido)-2-(4-hydroxyphenyl)acetamido)-3-((1-methyl-1H-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure; (6R,7R)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6S,7R)-7-[[(2S)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}(4-hydroxyphenyl)acetyl]amino}-3-[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl-3,4-didehydrocepham-4-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
| Therapeutic Class |
Antibiotics
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27N9O8S2
|
|||
| Canonical SMILES |
CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)NC3C4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O
|
|||
| InChI |
1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1
|
|||
| InChIKey |
GCFBRXLSHGKWDP-XCGNWRKASA-N
|
|||
| CAS Number |
CAS 62893-19-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5308397, 11212882, 11335303, 11360542, 11364333, 11366895, 11369457, 11371652, 11373802, 11377619, 11461514, 11485363, 11489580, 11490562, 11492137, 11495253, 29221788, 47348122, 47572074, 47645332, 50742183, 104301145, 125354991, 125354992, 144075466, 163193900, 175610906, 179038766, 223676922, 242145318, 244301341, 251960579
|
|||
| ChEBI ID |
CHEBI:3493
|
|||
| ADReCS Drug ID | BADD_D00389 | |||
| SuperDrug ATC ID |
J01DD12
|
|||
| SuperDrug CAS ID |
cas=062893190
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
|
Studied Microbe: Bacillus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Bacillus was decreased by Cefoperazone. | |||
|
Studied Microbe: Paenibacillaceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Cecal content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Paenibacillaceae was increased by Cefoperazone. | |||
|
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Staphylococcus was decreased by Cefoperazone. | |||
|
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Soft tissue or bone infection | |||
| Description | The abundance of Staphylococcus was increased by Cefoperazone. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Alistipes was decreased by Cefoperazone. | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroides was decreased by Cefoperazone. | |||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Bacteroides was decreased by Cefoperazone. | |||
|
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides caccae was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Cefoperazone dihydrate (adjusted p-values: 1.53E-03). | |||
|
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Cefoperazone dihydrate (adjusted p-values: 1.71E-04). | |||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Cefoperazone dihydrate (adjusted p-values: 1.33E-04). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Cefoperazone dihydrate (adjusted p-values: 7.71E-07). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Cefoperazone dihydrate (adjusted p-values: 4.73E-06). | |||
|
Studied Microbe: Barnesiella
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Barnesiella was decreased by Cefoperazone. | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Cefoperazone dihydrate (adjusted p-values: 2.79E-07). | |||
|
Studied Microbe: Porphyromonadaceae
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Porphyromonadaceae was decreased by Cefoperazone. | |||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Cefoperazone dihydrate (adjusted p-values: 1.19E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Bifidobacterium was decreased by Cefoperazone. | |||
|
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium adolescentis was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bifidobacterium longum was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Cefoperazone dihydrate (adjusted p-values: 2.74E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eggerthella lenta was decreased by Cefoperazone dihydrate (adjusted p-values: 2.90E-04). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Soft tissue or bone infection | |||
| Description | The abundance of Enterobacteriaceae was decreased by Cefoperazone. | |||
|
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Escherichia was increased by Cefoperazone. | |||
|
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli ED1a was decreased by Cefoperazone dihydrate (adjusted p-values: 5.22E-06). | |||
|
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Escherichia coli IAI1 was decreased by Cefoperazone dihydrate (adjusted p-values: 4.93E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Erysipelatoclostridium ramosum was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Turicibacteraceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Cecal content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Turicibacteraceae was decreased by Cefoperazone. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Cefoperazone dihydrate (adjusted p-values: 9.60E-07). | |||
|
Studied Microbe: Clostridiaceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Cecal content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridiaceae was decreased by Cefoperazone. | |||
|
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Clostridium difficile was increased by Cefoperazone. | |||
|
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Soft tissue or bone infection | |||
| Description | The abundance of Clostridium difficile was decreased by Cefoperazone. | |||
|
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Clostridium perfringens was decreased by Cefoperazone dihydrate (adjusted p-values: 5.52E-07). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Enterocloster bolteae was decreased by Cefoperazone dihydrate (adjusted p-values: 1.28E-05). | |||
|
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Eubacterium was decreased by Cefoperazone. | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Cefoperazone dihydrate (adjusted p-values: 1.01E-05). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Cefoperazone dihydrate (adjusted p-values: 3.85E-04). | |||
|
Studied Microbe: Lacrimispora saccharolytica
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lacrimispora saccharolytica was decreased by Cefoperazone dihydrate (adjusted p-values: 5.51E-07). | |||
|
Studied Microbe: Roseburia hominis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia hominis was decreased by Cefoperazone dihydrate (adjusted p-values: 3.71E-05). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Cefoperazone dihydrate (adjusted p-values: 3.01E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Cefoperazone dihydrate (adjusted p-values: 2.00E-05). | |||
|
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus gnavus was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Cefoperazone dihydrate (adjusted p-values: 5.77E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Fusobacteriales | ||||
|
Studied Microbe: Fusobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Fusobacterium was decreased by Cefoperazone. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Enterococcus was increased by Cefoperazone. | |||
|
Studied Microbe: Lactobacillaceae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Cecal content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillaceae was decreased by Cefoperazone. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Lactobacillus was decreased by Cefoperazone. | |||
|
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Lactobacillus paracasei was decreased by Cefoperazone dihydrate (adjusted p-values: 5.43E-05). | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Streptococcus was decreased by Cefoperazone. | |||
|
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus parasanguinis was decreased by Cefoperazone dihydrate (adjusted p-values: 1.67E-06). | |||
|
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Streptococcus salivarius was decreased by Cefoperazone dihydrate (adjusted p-values: 6.54E-07). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Mycobacteriales | ||||
|
Studied Microbe: Corynebacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Erysipelas and/or wound infection, pneumonia, urinary tract infection, and arthritis | |||
| Description | The abundance of Corynebacterium was decreased by Cefoperazone. | |||
|
Studied Microbe: Corynebacterium
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Soft tissue or bone infection | |||
| Description | The abundance of Corynebacterium was increased by Cefoperazone. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Pseudomonadales | ||||
|
Studied Microbe: Pseudomonas
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Pseudomonas was increased by Cefoperazone. | |||
|
Studied Microbe: Pseudomonas
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Soft tissue or bone infection | |||
| Description | The abundance of Pseudomonas was increased by Cefoperazone. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
|
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Veillonella parvula was decreased by Cefoperazone dihydrate (adjusted p-values: 5.04E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Akkermansia was decreased by Cefoperazone. | |||
|
Studied Microbe: Akkermansia muciniphila
Show/Hide Hierarchy
|
[6] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Akkermansia muciniphila was decreased by Cefoperazone dihydrate (adjusted p-values: 6.29E-06). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Clostridiales
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | C57BL/6 mice | Experimental Sample | Cecal content | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Clostridiales was decreased by Cefoperazone. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Target Info | Binder | [7] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Effect of cefoperazone on faecal flora. J Antimicrob Chemother. 1983 Aug;12(2):163-7. | |||
| REF 3 | Antibiotic-induced gut metabolome and microbiome alterations increase the susceptibility to Candida albicans colonization in the gastrointestinal tract. FEMS Microbiol Ecol. 2020 Jan 1;96(1):fiz187. | |||
| REF 4 | Impact of cefoperazone therapy on fecal flora. Antimicrob Agents Chemother. 1982 Aug;22(2):226-30. | |||
| REF 5 | Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile. mBio. 2015 Jul 14;6(4):e00974. | |||
| REF 6 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 7 | Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.